What Allogene Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 2 | 15 |
| Total trades | 2 | 17 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 95,400 |
| Disposed | 66,039 | 354,863 |
| Net activity | −66,039 | −259,463 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Oct 21 | Sale for tax withholding · S | −36,342 | $1.34 | −$48.7K | 1,045,877 |
| Douglas Earl Martin | SVP, General Counsel | Aug 21 | Sale for tax withholding · S | −29,697 | $2.12 | −$63K | 488,267 |
| Kazam Joshoa A | Director | Jun 18 | Exercise / conversion · M | +47,700 | — | — | 398,463 |
| Yoshiyama Annie | SVP, Finance | Apr 21 | Sale for tax withholding · S | −9,586 | $2.31 | −$22.1K | 124,517 |
| Beneski Benjamin Machinas | SVP, Chief Technical Officer | Mar 31 | Sale for tax withholding · S | −2,867 | $2.50 | −$7.17K | 195,338 |
| Chang David D | President and CEO | Mar 16 | Sale for tax withholding · S | −47,763 | $2.47 | −$118K | 5,150,599 |
| Beneski Benjamin Machinas | SVP, Chief Technical Officer | Mar 16 | Sale for tax withholding · S | −4,835 | $2.47 | −$11.9K | 198,205 |
| Beneski Benjamin Machinas | SVP, Chief Technical Officer | Mar 02 | Sale for tax withholding · S | −7,132 | $2.60 | −$18.5K | 203,040 |
| Douglas Earl Martin | SVP, General Counsel | Feb 02 | Sale for tax withholding · S | −22,900 | $1.76 | −$40.3K | 564,948 |
| Yoshiyama Annie | SVP, Finance | Feb 02 | Sale for tax withholding · S | −4,167 | $1.72 | −$7.17K | 130,322 |
| Roberts Zachary | EVP of R&D | Feb 02 | Sale for tax withholding · S | −35,700 | $1.77 | −$63.2K | 581,166 |
| Chang David D | President and CEO | Feb 02 | Sale for tax withholding · S | −95,269 | $1.80 | −$171K | 5,185,862 |
| Beneski Benjamin Machinas | SVP, Chief Technical Officer | Feb 02 | Sale for tax withholding · S | −7,549 | $1.73 | −$13.1K | 210,172 |
| Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Feb 02 | Sale for tax withholding · S | −24,001 | $1.76 | −$42.2K | 1,252,795 |
| Roberts Zachary | EVP of R&D | Jan 21 | Sale for tax withholding · S | −26,269 | $1.56 | −$41K | 616,866 |
| Kazam Joshoa A | Director | Dec 18 | Exercise / conversion · M | +47,700 | — | — | 350,763 |
| Beneski Benjamin Machinas | SVP, Chief Technical Officer | Nov 17 | Sale for tax withholding · S | −786 | $1.22 | −$959 | 217,721 |
| Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Oct 21 | Sale for tax withholding · S | −36,744 | $1.26 | −$46.2K | 1,276,796 |
| Messemer Deborah M. | Director | Jun 10 | Open-market sale · S | −36,885 | $1.42 | −$52.4K | 107,431 |
| Yoshiyama Annie | SVP, Finance | Apr 21 | Sale for tax withholding · S | −9,601 | $1.41 | −$13.5K | 130,663 |
Loading...
